Expertise in
66
conditions

Y J. Yuan

Kongjiang Road, 
Yangpu, CN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
66
conditions
Kongjiang Road, 
Yangpu, CN 

Overview

Y Yuan practices practicing medicine in Yangpu, China.

Dr. Yuan is highly rated in 66 conditions, according to our data. Their clinical expertise encompasses Stomach Cancer, Gallbladder Adenocarcinoma, Gastritis, Lithotripsy, and Endoscopy.

They are actively involved in clinical research, co-authoring 3213 peer reviewed articles and participating in 16 clinical trials.

Locations

Kongjiang Road, Yangpu, China
Other Locations
Union Hospital, Wuhan, 430022, China
State Key Laboratory Of Bioreactor Engineering, Shanghai, 200237, China
Suzhou Industrial Park, Suzhou, 215125, China
26 Hexing Road, Harbin, 150040, China
168 Changhai Road, Shanghai, 200433, China
5268 Renmin Street, Changchun, 130024, China
No. 68 Changle Road, Nanjing, 210006, China
5333 Xi'an Road, Changchun, 130062, China
Jiefang Road 238, Wuhan, 430060, China
49 North Garden Road, Haidian, China
No. 110, Ganhe Road, Hongkou, 200437, China
No. 36, San Hao Street, Shenyang, 110004, China
No.333 Longteng Road, Songjiang, 201620, China
324 Jingwu Road, Jinan, 250021, China
Qingchun Road No.79, Hangzhou, 310009, China
No. N1, Shangcheng Avenue, Yiwu, 322000, China
111 Dade Road, Guangzhou, 510120, China
Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
#79 Qingchun Road, Hangzhou, 310003, China
49 Huayuan North Road, Haidian, China
Siwangting Road 180, Yangzhou, 225002, China
No. 38 Xueyuan Road, Beijing, 100191, China
92 West Dazhi Street, Harbin, 150001, China
No.25 Taiping Street, Luzhou, 644300, China
12560, Fanhua Avenue, Hefei, China
Jingzhong Road, Jingzhou, 434000, China
68 Changle Road, Nanjing, 210006, China
Xingang Xi Road, Guangzhou, 510275, China
No. 2 Gaosuntang Road, Fuling, 408000, China
800 Dongchuan Road, Shanghai, 200240, China
No. 154 Anshan Road, Xiaobailou, 300052, China
No. 137 Liyushan South Road, Ueruemqi, 830054, China
Luoshi Road 122#, Wuhan, 430070, China
204 West Donggang Rd, Lanzhou, 730000, China
103 Mei Shan Road, Hefei, China
No.49 North Garden Street, Haidian, 100191, China
220 Handan Road, Shanghai, 200433, China
600 Tianhe Road, Guangzhou, 510630, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Recruiting
Publish Date: August 05, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Enrollment Status: Recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
Study Phase: Phase 2
A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: U3-1402
Study Phase: Phase 2
A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer
A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Biological
Study Drug: CF33-hNIS-antiPDL1
Study Phase: Phase 1
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug, Other
Study Drugs: carboplatin, nab-paclitaxel
Study Phase: Phase 2
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Letrozole, Palbociclib, Pembrolizumab
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Enobosarm, Pembrolizumab
Study Phase: Phase 2
A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer
A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Other, Drug
Study Drugs: Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

3211 Total Publications

Response characteristics of soil physicochemical properties after broad-leaved transformation of pure Cunninghamia lanceolata plantation in Dagangshan Region, Jiangxi, China.
Response characteristics of soil physicochemical properties after broad-leaved transformation of pure Cunninghamia lanceolata plantation in Dagangshan Region, Jiangxi, China.
Journal: Ying yong sheng tai xue bao = The journal of applied ecology
Published: August 25, 2026

Frequently Asked Questions about Y J. Yuan

Is Y J. Yuan a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Y J. Yuan is classified as an Distinguished expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Y J. Yuan participate in research or clinical trials?

Yes. Y J. Yuan has published 3211 articles and abstracts on conditions like Stomach Cancer. You can view a list of Y J. Yuan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yuan's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 58 Advanced Conditions
    View All 310 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile